Bayer donated $1 million to Donald Trump’s 2025 presidential inauguration — a first for the German pharmaceutical and chemical giant, which had never before contributed to an inaugural committee. Less than 14 months later, Trump signed an executive order prioritizing domestic production of glyphosate-based herbicides, the active ingredient in Bayer’s Roundup weedkiller. Meanwhile, Bayer proposed a $7.25 billion class settlement for Roundup cancer claims, with individual payouts ranging from roughly $10,000 to $165,000 depending on the claimant’s exposure history, age, and cancer severity.
The timing of these events has drawn sharp criticism from public health advocates and MAHA (Make America Healthy Again) supporters who view glyphosate as a cancer-causing chemical. Whether Bayer’s inauguration donation influenced the executive order is a matter of public debate, but the sequence of events — donation, settlement filing, presidential action — is documented and worth examining in detail. This article breaks down the donation, the executive order, the settlement structure and payout tiers, eligibility requirements, and what claimants should realistically expect.
Table of Contents
- Why Did Bayer Donate $1 Million to Trump’s Inauguration Before the Roundup Settlement?
- What Does Trump’s Glyphosate Executive Order Actually Do?
- How Is the $7.25 Billion Roundup Settlement Structured?
- What Are the Actual Roundup Payout Amounts by Tier?
- Who Is Eligible and What Could Go Wrong?
- How Bayer’s Lobbying Strategy Connects the Dots
- What Happens Next for Roundup Claimants and the Settlement
- Conclusion
- Frequently Asked Questions
Why Did Bayer Donate $1 Million to Trump’s Inauguration Before the Roundup Settlement?
Bayer’s $1 million donation to the 2025 trump inaugural committee was unprecedented for the company. According to CNBC’s reporting on inauguration donors, Bayer joined a wave of corporations — including Meta, Amazon, Target, Delta, and Ford — that contributed to the event. But Bayer’s donation stood out because of the company’s massive pending legal exposure. At the time, Bayer had already paid more than $11 billion resolving approximately 100,000 Roundup cancer claims, and tens of thousands more remained unresolved. The company was actively seeking a comprehensive class settlement to end the litigation once and for all. What followed the donation raises questions about corporate influence.
Bayer successfully lobbied the Trump administration for support to ensure the Supreme Court would hear its appeal in related Roundup litigation, according to US Right to Know’s investigation tracing Bayer’s ties to power in Trump’s Washington. Then on February 17, 2026, Bayer filed its proposed $7.25 billion class settlement in St. Louis. The very next day — February 18, 2026 — Trump signed an executive order directing the USDA to prioritize domestic production of glyphosate-based herbicides and elemental phosphorus. Bayer operates the only U.S. elemental phosphorus plant and is the dominant domestic glyphosate producer. The one-day gap between the settlement filing and the executive order is, at minimum, a remarkable coincidence.
What Does Trump’s Glyphosate Executive Order Actually Do?
Trump’s February 18, 2026 executive order directed the USDA to prioritize domestic production of glyphosate-based herbicides and elemental phosphorus. In practical terms, this positions Bayer — as the dominant U.S. producer of both — for favorable regulatory treatment and potential subsidies at a time when the company is simultaneously trying to cap its cancer liability through the courts. The order frames glyphosate production as a matter of agricultural security and domestic supply chain resilience. However, the order directly contradicts the public health messaging of Trump’s own MAHA movement.
Make america Healthy Again supporters, led by figures aligned with Robert F. Kennedy Jr.’s health advocacy, view glyphosate as a probable carcinogen linked to non-Hodgkin lymphoma — the very disease at the center of Bayer’s $7.25 billion settlement. Common Dreams reported that the executive order angered MAHA supporters who felt betrayed by the administration’s apparent prioritization of corporate interests over public health. The Texas Standard noted the tension between the administration’s stated health goals and its support for expanded herbicide production. If you are someone who supported the MAHA movement expecting a crackdown on chemical herbicides, this executive order moved in the opposite direction.
How Is the $7.25 Billion Roundup Settlement Structured?
Bayer filed its proposed $7.25 billion class settlement on February 17, 2026, in the 22nd Judicial Circuit Court of St. Louis, Missouri. This settlement is designed to cover both current plaintiffs and future claimants who are diagnosed with non-Hodgkin lymphoma within 16 years of final court approval. It is important to understand that this $7.25 billion is on top of the more than $11 billion Bayer has already paid in prior Roundup settlements resolving roughly 100,000 claims, bringing total Roundup-related payouts above $18 billion.
The payment schedule is staggered over many years. Bayer would deposit $500 million within 10 business days of preliminary court approval, followed by another $500 million by August 31, 2026. The remaining $6.25 billion would be paid over 16 annual installments ranging from $250 million to $550 million per year. For claimants, this means that even after the settlement is approved, full payouts will take years to distribute. As a specific example, someone filing a claim in 2027 might not receive their full payment until the late 2020s or early 2030s, depending on when their claim is processed within the installment schedule.
What Are the Actual Roundup Payout Amounts by Tier?
Individual payouts under the proposed settlement range from approximately $10,000 to $165,000, divided into nine tiers based on three factors: whether the claimant had occupational or residential exposure, their age at diagnosis, and how aggressive their NHL subtype was. The highest payouts — around $165,000 — go to agricultural, industrial, or turf workers with long-term occupational exposure who were diagnosed with aggressive NHL before age 60. For residential users — homeowners who sprayed Roundup on their lawns and gardens — the maximum payout caps at approximately $40,000. Residential users diagnosed between ages 60 and 77 with less aggressive forms of NHL can expect around $20,000.
Patients diagnosed at age 78 or older fall into the lowest tier at roughly $10,000. There is also a quick-pay option ranging from $6,000 to $14,500, available only to claimants who filed before February 13, 2026, which offers faster payment in exchange for a lower amount. The tradeoff is straightforward: if you need money now and your claim falls in a lower tier anyway, the quick-pay option might net you a comparable amount faster. But if your claim would qualify for a higher tier, accepting quick-pay means leaving significant money on the table.
Who Is Eligible and What Could Go Wrong?
To be eligible for the proposed settlement, claimants must have used Roundup before mid-February 2026 and been diagnosed with non-Hodgkin lymphoma. The settlement covers both people who have already filed lawsuits and future claimants diagnosed within 16 years of final court approval. However, there are significant uncertainties that claimants should understand before counting on any specific payout. First, the court has not yet granted preliminary approval of the settlement, and no hearing date has been set.
Until a judge signs off, this remains a proposal. Second, Bayer has built in an escape hatch: the company can cancel the entire settlement if too many plaintiffs opt out. This means that if a critical mass of claimants — particularly those with higher-value claims — decide they can do better in individual litigation, the deal could collapse entirely. Third, the 16-year installment schedule for the bulk of the funds means Bayer is effectively paying in future dollars while claimants wait. For someone diagnosed with an aggressive cancer, the prospect of waiting years for payment is not abstract — it is a serious limitation of this settlement structure.
How Bayer’s Lobbying Strategy Connects the Dots
The lobbying picture goes beyond the inauguration donation. According to US Right to Know’s investigation, Bayer actively worked the Trump administration on multiple fronts — pushing for Supreme Court intervention in Roundup cases, seeking favorable regulatory treatment for glyphosate, and positioning the company as essential to American agricultural infrastructure. The executive order signing one day after the settlement filing suggests a coordinated strategy in which legal, regulatory, and political efforts moved in parallel.
Consider the sequence from Bayer’s perspective: donate to the inauguration to build goodwill, lobby for Supreme Court support to strengthen your legal position, file a massive class settlement to cap future liability, and then benefit from a presidential executive order that protects your core product from regulatory threats. Each move reinforces the others. Whether or not any explicit quid pro quo occurred, the pattern illustrates how corporate political spending can create an environment where favorable policy outcomes follow naturally.
What Happens Next for Roundup Claimants and the Settlement
The immediate next step is court review. A judge in St. Louis must decide whether to grant preliminary approval of the $7.25 billion settlement, which would trigger a notice period during which class members can opt in or opt out. If preliminary approval is granted and the opt-out rate stays below Bayer’s threshold, the settlement moves toward final approval. If too many people opt out, Bayer can walk away from the deal entirely.
For people currently diagnosed with NHL who used Roundup, the decision of whether to participate in this class settlement or pursue individual litigation is the most consequential financial choice they will face. Individual lawsuits have historically produced much larger verdicts — some in the hundreds of millions — but they also take years, cost money, and carry the risk of losing. The class settlement offers certainty at a lower dollar amount. Meanwhile, the political dynamics surrounding glyphosate regulation remain volatile, with the MAHA movement and environmental groups pushing back against the Trump administration’s pro-glyphosate stance. How that political fight plays out could influence future litigation and regulatory decisions for years to come.
Conclusion
Bayer’s $1 million inauguration donation, followed by a favorable executive order signed one day after the company filed a $7.25 billion Roundup settlement, represents a textbook case of corporate influence operating across political, legal, and regulatory channels simultaneously. The settlement itself offers payouts ranging from $10,000 to $165,000 across nine tiers, with the highest amounts reserved for occupational users diagnosed young with aggressive NHL, and the lowest for elderly residential users. For Roundup claimants, the practical takeaway is this: the settlement is not yet approved, the payout amounts are modest compared to individual litigation verdicts, and the money will be distributed over 16 years.
Anyone eligible should carefully weigh the certainty of a class settlement payout against the possibility of a larger individual award. Consult with an attorney who handles mass tort cases — not one who found you through an advertisement — before making any decisions. And pay attention to the political landscape, because the same administration that signed an executive order boosting glyphosate production is now overseeing the regulatory environment in which these cancer claims will be evaluated.
Frequently Asked Questions
How much will I receive from the Roundup settlement?
Individual payouts range from approximately $10,000 to $165,000, depending on whether your exposure was occupational or residential, your age at NHL diagnosis, and how aggressive your cancer subtype is. Agricultural and industrial workers diagnosed before age 60 with aggressive NHL receive the highest tier. Residential users max out at about $40,000.
Is the Roundup settlement approved yet?
No. As of March 2026, Bayer has filed the proposed $7.25 billion settlement in St. Louis Circuit Court, but the court has not granted preliminary approval and no hearing date has been set. Bayer also reserves the right to cancel the settlement if too many claimants opt out.
What is the quick-pay option?
Claimants who filed before February 13, 2026 can elect a quick-pay option ranging from $6,000 to $14,500 for faster payment. This is a lower amount than the standard tiers but provides money sooner. It is only available to those who already had claims on file before the settlement was proposed.
How long will it take to receive a Roundup settlement payment?
Bayer would deposit $500 million within 10 business days of preliminary approval and another $500 million by August 31, 2026. The remaining $6.25 billion is paid over 16 annual installments. Individual claimants may wait months or years depending on when their claim is processed.
Did Bayer’s inauguration donation influence the glyphosate executive order?
There is no direct evidence of an explicit quid pro quo. However, the timeline is documented: Bayer donated $1 million to Trump’s inauguration (a first for the company), lobbied for Supreme Court support, filed the $7.25 billion settlement on February 17, 2026, and Trump signed the glyphosate executive order on February 18, 2026 — one day later. Public health advocates and MAHA supporters have criticized the apparent connection.
Can I still file a Roundup lawsuit instead of joining the settlement?
Yes. Claimants can opt out of the class settlement and pursue individual litigation. Individual lawsuits have historically produced larger verdicts, but they carry more risk, cost more, and take longer. The choice between class settlement and individual litigation depends on your specific circumstances and should be discussed with an experienced mass tort attorney.